The Global Market for Immunoassay Systems is Projected to Reach US$28 Billion by 2022
Increased Emphasis on Early Diagnosis of
Disease Conditions to Drive Growth in the Global Immunoassay Systems Market, According
to a New Report by Global
Industry Analysts, Inc.
GIA
launches comprehensive analysis of industry segments, trends, growth drivers,
market share, size and demand forecasts on the global Immunoassay Systems
market. The global market for Immunoassay Systems is projected
to reach US$28 billion by 2022,
driven by the growing incidence of chronic and infectious diseases, increased
emphasis on early diagnosis of disease conditions, development of novel
biomarkers, and improved access to healthcare & testing services in
developing countries.
Immunoassays
are test procedures based on the specific immuno-reaction between an
antibody(Ab) and an antigen(Ag), for the determination of amount of an analyte
in a test sample. The growth in the market is driven by the increasing
prevalence of chronic as well as infectious diseases, widespread application of
immunoassay in the field of oncology, quick analysis and affordability of
immunoassay, and technological developments. The market continues to benefit
from fast paced technology developments which promise to bring new opportunities
for growth. With rising emphasis on lab automation, demand for automated
immunoassay systems is expected to grow in the coming years. Rapid Tests
represent the fastest growing segment of the global immunoassays market. The growth
in the chemiluminescence (CLIA) assay segment is supported by advantages such as high
sensitivity, automation and speed. Leading vendors continue to discover and
validate novel biomarkers, develop assays for new biomarkers and add assays to
instrument menus. The new generation portable systems are fast and capable of
detecting new disease states. Portable systems are also capable of analyzing
small sample size with high accuracy. The ongoing consolidation in the
healthcare industry is creating the need for higher volume testing in labs
thereby driving demand for immunoassay analyzers with improved functionality
and faster throughputs. Technologies are also being upgraded to provide an extensive
menu of tests at a faster rate. Demand for multiplex immunoassay is on rise supported
by the growing need for better disease analytic procedures in addition to
reduced errors and lower costs.
As
stated by the new market research report on Immunoassay Systems, the United States represents the largest market worldwide. Asia-Pacific
is projected to witness the fastest growth with a CAGR of 10.6% over the analysis
period, led by factors such as improving healthcare infrastructure, increased
healthcare spending, focus on effective management of chronic diseases and rising trend of medical tourism.
Major
players covered in the report include Abbott Laboratories, Beckman Coulter
Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc.,
Roche Diagnostics, Siemens Healthcare Diagnostics, Sysmex Corporation, Quidel
Corporation, DiaSorin S.p.A, and Tosoh Bioscience Inc., among others.
The
research report titled “Immunoassay Systems: A Global Strategic Business
Report” announced by Global Industry
Analysts Inc., provides a comprehensive
review of market trends, issues, drivers, mergers, acquisitions and other
strategic industry activities of major companies worldwide. The report provides
market estimates and projections for all major geographic markets including the
United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia
and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific),
Latin America (Brazil and Rest of Latin America), and Rest of World. Product
segments analyzed include Enzyme Immunoassay, Fluorescence Immunoassay,
Chemiluminescence Immunoassay, Rapid Tests, ELISPOT, PCR, and Others.
Comments
Post a Comment